Daraasad: Malaayiin bukaannada kansarka naasaha ah oo qaab cusub loo daaweyn karo

Malaayiin qof oo qaba kansarka naasaha ayaa si ammaan ah uga maarmi kara kiimoterabiga (chemotherapy), kaddib markii saynisyahannadu sameeyeen baaritaan DNA ah oo kala saari kara bukaannada ay u badan tahay inay ka faa'iidaystaan daaweyntan iyo kuwa aan uga faa'iidaysan doonin, sida ay muujiyeen natiijooyinka tijaabada.

Daraasaddan caalamiga ah ayaa ogaatay in in ka badan saddex meelood laba meel ka qaybgalayaashii daraasadda laga badbaadin karo dhibaatooyinka iyo waxyeellooyinka kiimoterabiga, iyadoo lagu daaweyn karo daaweynta hormoonnada oo keliya.

Kiimoterabigu waxa uu sababi karaa daal badan, lalabbo, timo-daadasho, daciifnimo ku timaadda hab-dhiska difaaca jirka, iyo dhibaatooyin la xiriira taranka iyo uur-qaadista.

Daraasadda, oo ay hoggaaminaysay University College London, ayaa lagu sameeyay in ka badan 4,000 oo bukaan oo dhawaan laga helay kansarka naasaha, kuwaas oo da'doodu ka weynayd 40 sano. Ka qaybgalayaashu waxay ka kala yimaadeen United Kingdom, Norway, Sweden, Australia, New Zealand iyo Thailand.

Saynisyahannadu waxay isticmaaleen baaritaan hidde-side ah oo lagu magacaabo Prosigna si ay u cabbiraan firfircoonida 50 hidde-side oo ku lug leh koritaanka kansarka naasaha, isla markaana ay u xisaabiyaan halista bukaanka uga iman karta in cudurku dib u soo noqdo.

Kuwa helay dhibco hoose — kuwaas oo ahaa laba meelood saddex meel ka badan dhammaan kooxda — lama siin daaweynta kiimoterabiga. Heerka badbaadada ee shanta sano ee kooxdan wuxuu ahaa 93.7%, marka loo eego 94.9% ee bukaannadii helay kiimoterabi qayb ka ah daaweyntooda.

Daaweynta ugu muhiimsan ee kansarka naasaha badanaa waa qalliin lagu saaro burooyinka. Inta badan kiimoterabiga waxaa lagu taliyaa qalliinka ka dib si loo yareeyo khatarta ah in kansarku dib u soo noqdo.

Sidoo kale waxaa si joogto ah loo siiyaa dadka qaba kansarka naasaha ee marxaladda hore, gaar ahaan marka uu ku faafo qanjirrada limfiga ee u dhow.

Dhakhaatiirta ayaa ka walaacsan in daaweyntani faa'iido yar u leedahay dadka qaba nooca ugu badan ee kansarka naasaha, sida ay sheegtay University College London.

Jaamacaddu waxay sheegtay in in ka badan 5,000 oo bukaan oo sanad kasta ka tirsan National Health Service ay ka maarmi karaan kiimoterabiga iyadoo la adeegsanayo natiijooyinka tijaabadan.

Karen Bonham oo ka soo jeedda Cardiff, kana qayb qaadatay tijaabada, ayaa sheegtay in natiijooyinku yihiin "farxad iyo nafis weyn" isla markaana ay dareemayso "sida maalinta Kirismaska".

Haweeneydan 64 jirka ah ayaa ka badbaadday kiimoterabiga iyadoo ay uga mahadcelinayso baaritaanka Prosigna. Halkii kiimoterabi laga siin lahaa, waxay heshay daaweynta shucaaca iyo daaweynta hormoonnada muddo siddeed sano ah.

"Marka lagu sheego inaad qabto kansar iyo marka daaweyntu bilaabato waxay noqon kartaa wax aad u naxdin badan," ayay tiri.

"Runtii waxay kugu riixaysaa adduun ay ka buuxaan hubanti la'aan. Mudnaanta noloshaadu way is beddeshaa — waxa keliya ee aad rabto waa inaad noolaato."

Natiijooyinka daraasaddan ayaa lagu soo bandhigi doonaa shirweynaha ugu weyn ee kansarka adduunka, kaas oo ay qabato American Society of Clinical Oncology sanad walba. Shirkan ayaa ka dhici doona Chicago ee United States maalinta Sabtida.

Professor David Miles, oo ah khabiir caan ah oo ku takhasusay kansarka, ayaa natiijooyinkan ku tilmaamay kuwo "si weyn u beddeli doona habka daaweynta loo maareeyo".

"Waxaan hadda si kalsooni leh u saadaalin karnaa in bukaanno badan aysan wax faa'iido ah ka heli doonin kiimoterabiga, sidaas darteedna aysan jirin baahi ay ugu maraan daaweyntaas," ayuu u sheegay barnaamijka BBC ee Newshour.

Wuxuu intaa ku daray in baaritaankani uu dhakhaatiirta u oggolaan doono inay "si kalsooni leh u aqoonsadaan koox weyn oo haween ah oo aan wax faa'iido ah ka heli doonin kiimoterabiga, isla markaana aan loo baahnayn inay maraan dhammaan dhibaatooyinka iyo waxyeellooyinka daaweyntaas iyadoo aan faa'iido laga helayn."

"Waagii hore waxaan siin jirnay kiimoterabi 100 haween ah si ay uga faa'iideystaan 10 keliya, annagoo og in 90-ka kale aysan u baahnayn," ayuu yiri.

Tanya Hutson, oo laga helay kansarka naasaha sannadkii 2022 isla markaana kiimoterabi qayb ka ahaa daaweynteeda, ayaa baaritaanka cusub ee DNA-da ku tilmaantay "wax cajiib ah oo aan caadi ahayn."

"Waxay si dhab ah u muujinaysaa waxa dhaca marka lacag lagu maalgeliyo cilmi-baarista," ayay tiri, iyadoo raacisay in kiimoterabigu uu ahaa "mid aad u adag oo xanuun badan."

"Dhammaan dadka aan u baahnayn daaweyntan balse weli la siinayo — tani waa isbeddel weyn oo wax walba beddeli kara."

Si kastaba ha ahaatee, sida ay sheegtay University College London, weli lama oga in natiijooyinkan ay khuseeyaan dadka ka yar 40 sano jir, waxaana la filayaa in jawaab cad laga helo arrintan dhowr sano kadib.